UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver

International journal of molecular sciences, 2018-07, Vol.19 (8), p.2199

2018

Volltextzugriff (PDF)

Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease

Clinical gastroenterology and hepatology, 2011, Vol.9 (1), p.30-35

2011

Volltextzugriff (PDF)

Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease

Journal of Crohn's and colitis, 2013-11, Vol.7 (10), p.769-779

2013

Volltextzugriff (PDF)

Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches

Therapeutic Advances in Gastroenterology, 2021, Vol.14, p.17562848211006669-17562848211006669

2021

Volltextzugriff (PDF)

Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach

Italian journal of pediatrics, 2021-01, Vol.47 (1), p.18-18, Article 18

2021

Volltextzugriff (PDF)

Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy

Nutrients, 2020-10, Vol.12 (11), p.3277

2020

Volltextzugriff (PDF)

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

United European gastroenterology journal, 2019-11, Vol.7 (9), p.1189-1197

2019

Volltextzugriff (PDF)

Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study

Journal of Crohn's and colitis, 2016-08, Vol.10 (8), p.913-924

2016

Volltextzugriff (PDF)

Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study

Gastroenterology research and practice, 2018-01, Vol.2018 (2018), p.1-7

2018

Volltextzugriff (PDF)

Glucagon-like peptide-2 analogues for Crohn's disease patients with short bowel syndrome and intestinal failure

World journal of gastroenterology : WJG, 2022-11, Vol.28 (44), p.6258-6270

2022

Volltextzugriff (PDF)

What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?

World journal of gastrointestinal pharmacology and therapeutics, 2016-08, Vol.7 (3), p.387-396

2016

Volltextzugriff (PDF)

Dual Targeted Therapy in Patient With Extensive Crohn’s Disease: Different Response at Distinct Location

Inflammatory bowel diseases, 2021-07, Vol.27 (8), p.e93-e94

2021

Volltextzugriff (PDF)

Management of perianal fistulas in Crohn's disease: an up-to-date review

World journal of gastroenterology : WJG, 2015-02, Vol.21 (5), p.1394-1403

2015

Volltextzugriff (PDF)

Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors

Current medical research and opinion, 2020-01, Vol.36 (1), p.7-8

2020

Volltextzugriff (PDF)

Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future

Expert review of clinical immunology, 2017-03, Vol.13 (3), p.223-233

2017

Volltextzugriff (PDF)

Fever of unknown origin due to Coxiella burnetii, an unexpected guest in primary sclerosing cholangitis

Digestive and liver disease, 2023-01, Vol.55 (1), p.131-132

2023

Volltextzugriff (PDF)

Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2021-02, Vol.15 (2), p.335-339

2021

Volltextzugriff (PDF)

Serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients

Alimentary pharmacology & therapeutics, 2021-01, Vol.53 (2), p.273-280

2021

Volltextzugriff (PDF)

Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases

Journal of clinical medicine, 2021-02, Vol.10 (4), p.853

2021

Volltextzugriff (PDF)

TRPM7 is overexpressed in human IBD-related and sporadic colorectal cancer and correlates with tumor grade

Digestive and liver disease, 2020-10, Vol.52 (10), p.1188-1194

2020

Volltextzugriff (PDF)

Treatment of Crohn's disease with colony-stimulating factors: An overview

Therapeutics and clinical risk management, 2008-10, Vol.4 (5), p.927-934

2008

Volltextzugriff (PDF)

TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine

EBioMedicine, 2019-03, Vol.41, p.40-41

2019

Volltextzugriff (PDF)

1 – 25 von 217

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(190)
Mit Volltextzugriff
(181)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver

Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease

Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease

Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches

Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach

Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Adalimumab in active ulcerative colitis: A “real-life” observational study

Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study

Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study

Glucagon-like peptide-2 analogues for Crohn's disease patients with short bowel syndrome and intestinal failure

What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?

Dual Targeted Therapy in Patient With Extensive Crohn’s Disease: Different Response at Distinct Location

Management of perianal fistulas in Crohn's disease: an up-to-date review

Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors

Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future

Fever of unknown origin due to Coxiella burnetii, an unexpected guest in primary sclerosing cholangitis

Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case–Control IG-IBD Study

Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease

Serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients

Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases

TRPM7 is overexpressed in human IBD-related and sporadic colorectal cancer and correlates with tumor grade

Treatment of Crohn's disease with colony-stimulating factors: An overview

TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine

The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar

Suchergebnisse filtern